释放抗体-药物偶联物的潜力

ADC review Pub Date : 2023-09-26 DOI:10.14229/jadc.2023.26.020

Toshimitsu Uenaka, Ph.D

{"title":"释放抗体-药物偶联物的潜力","authors":"Toshimitsu Uenaka, Ph.D","doi":"10.14229/jadc.2023.26.020","DOIUrl":null,"url":null,"abstract":"One hundred years ago, Paul Ehrlich*, a German biochemist and Nobel laureate who created the field of chemotherapy, coined the term “magic bullet.” He envisioned that a drug could specifically target a particular pathogen without affecting normal host cells. Antibody drug conjugates (ADCs) are the realization of Ehrlich’s vision for therapies that target tumor cells with precision and specificity.","PeriodicalId":500860,"journal":{"name":"ADC review","volume":"31 18 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unlocking the Potential of Antibody-Drug Conjugates\",\"authors\":\"Toshimitsu Uenaka, Ph.D\",\"doi\":\"10.14229/jadc.2023.26.020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"One hundred years ago, Paul Ehrlich*, a German biochemist and Nobel laureate who created the field of chemotherapy, coined the term “magic bullet.” He envisioned that a drug could specifically target a particular pathogen without affecting normal host cells. Antibody drug conjugates (ADCs) are the realization of Ehrlich’s vision for therapies that target tumor cells with precision and specificity.\",\"PeriodicalId\":500860,\"journal\":{\"name\":\"ADC review\",\"volume\":\"31 18 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ADC review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14229/jadc.2023.26.020\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ADC review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14229/jadc.2023.26.020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

100年前，创造了化疗领域的德国生物化学家、诺贝尔奖得主保罗·埃利希(Paul Ehrlich) *创造了“魔弹”这个词。他设想一种药物可以专门针对特定的病原体而不影响正常的宿主细胞。抗体药物偶联物(adc)实现了Ehrlich对精确和特异性靶向肿瘤细胞的治疗愿景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Unlocking the Potential of Antibody-Drug Conjugates

One hundred years ago, Paul Ehrlich*, a German biochemist and Nobel laureate who created the field of chemotherapy, coined the term “magic bullet.” He envisioned that a drug could specifically target a particular pathogen without affecting normal host cells. Antibody drug conjugates (ADCs) are the realization of Ehrlich’s vision for therapies that target tumor cells with precision and specificity.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ADC review

自引率

0.00%

发文量